Monica Scholz
Family · Hiawatha, KSNPI 1760068308
Payments from drug & device makers
Across 69 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$247
- Novo Nordisk$115
- AstraZeneca$98
- Otsuka America Pharmaceutical, Inc.$80
- Novartis$77
- Amgen$75
- plus $498 from 17 others
What the payments were for
- Food & beverage$1,190100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 13 | $247 |
| Novo Nordisk | 8 | $115 |
| AstraZeneca | 7 | $98 |
| Otsuka America Pharmaceutical, Inc. | 4 | $80 |
| Novartis | 5 | $77 |
| Amgen | 5 | $75 |
| Lilly USA, LLC | 4 | $69 |
| Lundbeck LLC | 4 | $64 |
| Boehringer Ingelheim | 3 | $47 |
| Sanofi Pasteur Inc. | 1 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Sanofi | 1 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Johnson & Johnson | 1 | $26 |
| Dexcom, Inc. | 1 | $18 |
| GSK | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
| Electromed, Inc. | 1 | $14 |
| Exact Sciences | 1 | $13 |
How this compares
$1,190 in reported general payments places this provider in the 75th percentile of 1,579 family providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 65 | $32,408 |
| OzempicSemaglutide | 32 | $31,270 |
| MounjaroTirzepatide | 18 | $19,952 |
| FarxigaDapagliflozin Propanediol | 18 | $10,285 |
| DapagliflozinDapagliflozin Propanediol | 14 | $7,529 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $7,390 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $5,684 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,306 |
| Erythromycin Ethylsuccinate | 12 | $3,164 |
| Humalog Kwikpen U-100Insulin Lispro | 13 | $2,692 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $2,531 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $2,431 |
| VascepaIcosapent Ethyl | 14 | $2,426 |
| Memantine Hcl | 21 | $2,405 |
| Dexlansoprazole DrDexlansoprazole | 13 | $2,150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $115 | $31,27032 claims |
| Lilly USA, LLCMounjaro | $69 | $19,95218 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $98 | $17,67629 claims |
| GSKBreo Ellipta | $18 | $4,30611 claims |
| Boehringer IngelheimSynjardy Xr | $47 | $2,53112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,579 family providers in Kansas.
Other family in Hiawatha
- Zohra HussainiKansas City$329K
- Jennifer ChesterOverland Park$327K
- Amanda CaldwellLeawood$203K
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Tatum TolandTopeka$108K
- Mary GonzalesWichita$87K
- Erin FeitzOverland Park$36K
- Adam CaseKansas City$34K
- Jaimie HeldstabWestwood$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.